IMPACT OF SGLT2 INHIBITORS ON MORTALITY IN PULMONARY ARTERIAL HYPERTENSION: EXPLORING THE ASSOCIATIONIRAKLI LEMONJAVA, Zurab Azmaiparashvili, Nino Gudushauri et al.|CHEST Journal|2024Cited by 1
EXPLORING THE ASSOCIATION BETWEEN ELEVATED COPD EXACERBATION RISK AND COMMONLY PRESCRIBED MUSCLE RELAXANTSIRAKLI LEMONJAVA, Zurab Azmaiparashvili, Nino Gudushauri et al.|CHEST Journal|2024Cited by 0
US-COHORT ANALYSIS: FIVE-YEAR OUTCOMES OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND LUNG CANCER PRESCRIBED ANTIFIBROTICSGlenn Eiger, Jose Manuel Martinez Manzano, RAUL LEGUIZAMON et al.|CHEST Journal|2025Cited by 0
DOES A SINGLE HIGH BLOOD MONOCYTE COUNT IN PATIENTS WITH CORONARY ARTERY DISEASE CONFER A HIGHER RISK FOR INTERSTITIAL LUNG DISEASE AND PULMONARY FIBROSIS?Zurab Azmaiparashvili, John Malin, Justin Riley Lam et al.|CHEST Journal|2025Cited by 0
GLP-1 RECEPTOR AGONISTS AND RISK OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM IN TYPE 2 DIABETES: EVIDENCE FROM A LARGE, REAL-WORLD DATABASE ANALYSISIRAKLI LEMONJAVA, Nino Gudushauri, Irakli Tskhakaia et al.|CHEST Journal|2025Cited by 0